From Trial-and-Error to Predictive Biologics Engineering
Biologics development has entered a new era. While computational drug design (CDD) has supported biologics discovery for years, the rapid advancement of artificial intelligence (AI) and machine learning (ML) is fundamentally changing how scientists identify, optimize, and progress therapeutic candidates.
Across the industry, companies are moving beyond isolated AI pilot programs and integrating AI-enabled workflows into core discovery strategies. Recent collaborations between organizations such as Eli Lilly, Chai Discovery, BigHat Bio, Bayer, Cradle, and Latent Labs highlight growing confidence that AI can accelerate biologics design, improve developability, and reduce the experimental burden traditionally associated with drug discovery.
This shift forms the foundation of discussions at the CDD & AI for Biologics Summit, where computational biologists, data scientists, developability experts, and AI innovation leaders will explore how AI and computation can work together to design next-generation biologics with greater confidence and efficiency.
The Growing Complexity of Biologics Demands Better Tools
Modern biologics are becoming increasingly sophisticated. Beyond traditional monoclonal antibodies, discovery teams are now developing bispecifics, multispecifics, antibody-drug conjugates (ADCs), T-cell engagers, and engineered protein therapeutics.
As molecule complexity increases, so does the challenge of balancing multiple objectives simultaneously. Scientists are no longer optimizing solely for potency or binding affinity. Today's candidates must also demonstrate manufacturability, stability, low immunogenicity risk, favorable formulation characteristics, and scalability for downstream CMC activities.
Optimizing all these characteristics through conventional experimental approaches alone can be resource-intensive and time-consuming. AI and computational methods offer a way to evaluate thousands of possibilities before molecules ever enter the laboratory, allowing teams to focus effort on the most promising candidates.
Multi-Objective Optimization Is Becoming the New Standard
One of the most significant trends in biologics discovery is the move toward multi-objective optimization.
Historically, drug discovery programs often prioritized affinity and addressed developability challenges later in the process. This frequently resulted in promising candidates failing during scale-up, formulation, or manufacturing.
Today's AI-enabled approaches aim to evaluate multiple parameters simultaneously, helping teams identify liabilities earlier and engineer candidates with stronger overall profiles. Computational and AI tools are increasingly being used to predict aggregation risk, stability profiles, antigen binding performance, immunogenicity potential, formulation compatibility, and manufacturing suitability.
By integrating these predictions earlier in discovery, organizations can make more informed decisions and reduce downstream development risk. This evolution toward "developability by design" is rapidly becoming a key competitive advantage in biologics R&D.
AI Is Accelerating the Design-Make-Test-Analyze Cycle
The traditional Design-Make-Test-Analyze (DMTA) cycle can be both expensive and iterative. AI is helping organizations shorten this cycle by generating hypotheses, prioritizing experiments, and learning from experimental outcomes more efficiently.
Many organizations are now exploring closed-loop systems where machine learning models continuously improve using high-throughput experimental data. These workflows allow teams to generate candidate molecules in silico, predict key properties before synthesis, prioritize experimental validation, feed new data back into models, and continuously improve prediction accuracy.
This combination of AI-guided design and wet-lab validation creates a more agile discovery environment where learning happens faster and scientific decisions are supported by larger, richer datasets.
Why Data Quality Matters More Than Model Complexity
Despite the excitement surrounding generative AI and large language models for biology, many leaders across the biologics community agree that data quality remains the foundation of successful AI implementation.
Even the most advanced algorithms can struggle when trained on incomplete, inconsistent, or poorly annotated datasets.
As a result, organizations are investing heavily in laboratory automation, standardized data generation, high-throughput screening capabilities, data infrastructure modernization, and AI-ready biological datasets.
The goal is to create reliable data ecosystems that allow AI models to generate insights with greater confidence and reproducibility. As biologics organizations scale their AI capabilities, data readiness is increasingly becoming a strategic priority rather than simply a technical challenge.
Molecular Dynamics and Physics-Based Modeling Remain Critical
While AI is attracting significant attention, computational experts continue to emphasize the importance of physics-based approaches.
Molecular dynamics simulations, structure-based modeling, and biophysical analyses remain essential for understanding complex biological systems and validating AI predictions. In many cases, hybrid approaches that combine machine learning with structural and physicochemical data are producing the strongest results.
For biologics developers, the future is unlikely to be AI versus traditional computational methods. Instead, the greatest value will come from combining these approaches to generate more accurate predictions and stronger scientific confidence.
Building Confidence in AI-Driven Biologics Development
As AI becomes more deeply embedded within biologics discovery programs, a critical question remains: when can researchers trust AI-generated recommendations?
The industry is increasingly focused on understanding where AI delivers reliable value and where human expertise remains essential. Areas such as model interpretability, confidence scoring, experimental validation, and regulatory acceptance continue to be major discussion points.
The organizations that succeed will likely be those that develop balanced workflows combining AI innovation, computational rigor, and scientific expertise. Human-in-the-loop systems, where researchers guide and validate AI-generated outputs, are emerging as a preferred model for ensuring both speed and scientific integrity.
The next generation of biologics will not be discovered through AI alone, nor through traditional computational approaches in isolation.
Instead, success will come from effectively integrating AI, computational drug design, developability assessment, laboratory automation, and experimental science into unified discovery ecosystems.
This convergence is already transforming how organizations design proteins, predict molecular properties, optimize candidates, and advance therapies toward clinical development. As these technologies mature, biologics discovery is shifting from reactive experimentation toward predictive engineering.
Join the Leaders Driving AI-Enabled Biologics Discovery
This August, the CDD & AI for Biologics Summit will bring together computational drug design experts, AI/ML innovators, biologics discovery leaders, and developability specialists who are shaping the future of the industry.
Attendees will hear insights from organizations including AbbVie, Amgen, Genentech, GSK, Merck, Novartis, Regeneron, Takeda, UCB, Eli Lilly, Chai Discovery, insitro, Insilico Medicine, Gilead Sciences, 3T Biosciences, and the Institute for Protein Innovation.
Whether you're focused on antibody engineering, protein design, AI model development, developability assessment, molecular modeling, or advancing biologics toward derisked CMC, this is the premier forum to learn how AI and computational science are redefining the future of biologics discovery.
Discover the 2026 Agenda
Catch the latest industry breakthroughs, emerging trends and exclusive insights by participating in our dynamic roundtables and panel discussions.
Prioritize Partnering With Us
As the field rapidly expands and matures, position yourself alongside leading solution providers to ensure your brand stands out as a premier choice, amid growing competition.
Join Your Community
Immerse yourself in critical conversations with like-minded experts spanning all stages of development, from in silico to de novo biologics design and developability optimization, and build invaluable connections.